Peripheral ulcerative keratitis in rheumatoid arthritis: successful use of intravenous cyclophosphamide and comparison of clinical and serological characteristics

CASE REPORTS All patients received systemic immunosuppressive treatment with intravenous cyclophosphamide and the dose was dependent on age, weight, renal function, and clinical response. Azathioprine, 5, 6 methotrexate, 7, 8 and ciclosporin 8 have been used with varying success, but cyclophosphamid...

Full description

Saved in:
Bibliographic Details
Published in:Annals of the rheumatic diseases 2005-06, Vol.64 (6), p.961-962
Main Authors: Clewes, A R, Dawson, J K, Kaye, S, Bucknall, R C
Format: Article
Language:English
Subjects:
Age
Aged
Aged, 80 and over
Arthritis, Rheumatoid - drug therapy
Arthritis, Rheumatoid - immunology
corneal melt
Corneal Ulcer - drug therapy
Corneal Ulcer - immunology
Cyclophosphamide - therapeutic use
Female
Humans
Immunosuppressive Agents - therapeutic use
Letter
Male
Middle Aged
Mortality
peripheral ulcerative keratitis
Rheumatoid arthritis
vasculitis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:CASE REPORTS All patients received systemic immunosuppressive treatment with intravenous cyclophosphamide and the dose was dependent on age, weight, renal function, and clinical response. Azathioprine, 5, 6 methotrexate, 7, 8 and ciclosporin 8 have been used with varying success, but cyclophosphamide 1, 6, 9 has been widely used in destructive ocular inflammatory conditions and has a well established role in treating systemic vasculitis. 10 Systemic and local steroids are used but we have concerns about the reduction in cornea healing, and steroids alone do not alter mortality. 1 We found no incidence of infection or immunosuppressive complication.
ISSN:0003-4967
1468-2060
DOI:10.1136/ard.2004.023283